HEALTH PROFESSIONAL · SOURCE READING
Components of the transplant process
Source: Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
An expert panel review of indications for HSCT was published in 2012.[88] Components of the transplant process that have been shown to be important in improving or predicting outcome of HSCT for children with ALL include the following:
Source links and citations
Total-body irradiation (TBI)-containing transplant preparative regimens.
Source links and citations
MRD detection just before transplant.
Source links and citations
MRD detection posttransplant.
Source links and citations
Donor type and HLA match.
Source links and citations
Role of GVHD/graft-versus-leukemia (GVL) in ALL and immune modulation after transplant to prevent relapse.
An analysis from the CIBMTR examined pretransplant variables to create a model for predicting LFS posttransplant in pediatric patients (aged <18 years). All patients were first transplant recipients who had myeloablative conditioning, and all stem cells sources were included. For patients with ALL, the predictors associated with lower LFS included age younger than 2 years, second CR or higher, MRD positivity (only in second CR, not in first CR), and presence of morphologically detectable disease at time of transplant. A scale was established to stratify patients on the basis of risk factors to predict survival. The 5-year LFS rate was 68% for the low-risk group, 51% for the intermediate-risk group, and 33% for the high-risk group.[89]
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice
Triangle